Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 8/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451976 | 1.00 | FAAH (0.48) | FAAHSPHK2SPHK1TLR7HDAC8 | |
| SCHEMBL452456 | 0.88 | SPHK2 (0.61) | SPHK2SPHK1 | |
| SCHEMBL449569 | 0.88 | SPHK2 (0.61) | SPHK2SPHK1 | |
| SCHEMBL453900 | 0.86 | SPHK2 (0.47) | FAAHSPHK2SPHK1HRH3 | |
| SCHEMBL451690 | 0.86 | HRH3 (0.54) | HRH3 | |
| SCHEMBL453568 | 0.85 | SPHK1 (0.57) | SPHK2SPHK1 | |
| SCHEMBL447985 | 0.79 | SPHK1 (0.47) | SPHK2SPHK1HRH3 | |
| SCHEMBL448521 | 0.78 | HRH3 (0.66) | HRH3 | |
| SCHEMBL450172 | 0.78 | HRH3 (0.57) | HRH3 | |
| SCHEMBL450171 | 0.78 | HRH3 (0.54) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | claimed |
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | FAAH 1132/4885SPHK2 22/4885SPHK1 9/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | FAAH 1270/4885SPHK2 20/4885SPHK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.